ALXN1840

Wilmette, Illinois, USA, April 19, 2026 In a significant advancement for rare disease therapeutics, Monopar Therapeutics Inc. has presented...

WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...